
    
      This is an interventional, single arm, open-label, non-randomized, phase II study to
      accumulate additional data on immunogenicity and safety of Ad26.ZEBOV/MVA-BNÂ®-Filo against
      Ebola virus disease.

      It also has a qualitative component to better understand knowledge about Ebola virus disease
      and the perception and attitudes towards the vaccine amongst participants (Healthcare and
      Frontline workers).
    
  